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ABSTRACT 
Human immunodeficiency virus type 1 (HIV-1) is the cause of an estimated 1.9 million 
deaths in the world annually. The HI virus has three enzymes, notably; reverse 
transcriptase, integrase and protease, which are crucial for its maturation and continued 
infection. HIV relies on the catalytic efficacy of the protease enzyme for cleaving 
precursor polyproteins to yield structural and functional proteins. Inhibition of the viral 
protease proffers major therapeutic benefits in the battle against HIV. However, the use 
of protease inhibitors in HIV regimens is limited by the emergence of drug resistant 
mutations in the protease coding region. Drug resistant mutations are characterized by 
amino acid substitutions, deletions, and/or insertions in the viral sequence. Thus, this 
study set out to assess structural and functional characteristics of an HIV-1 South African 
subtype C (C-SA) protease with a single amino acid substituted and another inserted at 
codon  36, i.e., I36TT, with respect to the wild-type HIV-1 C-SA protease. An I36TT 
protease was generated with its background polymorphisms (P39S, D60E, and Q61E), 
over-expressed, and purified. Secondary and tertiary structural properties of the wild-type 
and the variant protease were evaluated using far-UV circular dichroism and fluorescence 
spectroscopy. Both proteases exhibited typical secondary structural features of a 
predominantly β-sheeted protein, indicated by circular dichroism spectra with minima at 
216 nm. Using intrinsic tryptophan as a probe, the tertiary structures of both proteases 
revealed that the local structural environments of both proteases had not been perturbed. 
This was indicated by fluorescence emission intensity peak at 355 nm. Proteolytic 
efficiency of the protease enzymes was evaluated following hydrolysis of a synthetic 
chromogenic HIV substrate mimicking the conserved protease cleavage site in the gag-
pol polyprotein precursor. A comparison of the kinetic properties of the enzymes 
indicated that the I36TT variant protease has a slightly (7%) enhanced catalytic activity 
relative to the wild-type HIV-1 C-SA protease. Enzymatic parameters of the two 
proteases in the presence of various protease-inhibitors showed that both proteases’ 
catalytic activity is highly affected by saquinavir with IC50 values of 7.6 nM and 6.3 nM 
for the wild-type and the variant, respectively. The variant protease enzyme, compared to 
the wild-type, appears to have acquired resistance towards indinavir with IC50 value of 
16.2 nM and 9.5 nM for the variant and wild-type, respectively. In the presence of 
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ritonavir, the variant protease (IC50 value of 36.4 nM) proved to have retained most of its 
enzymatic characteristic as compared to the wild-type protease (IC50 value of 19.1 nM). 
The wild-type and variant protease enzymes showed similar susceptibility (IC50 value of 
17.3 and 16.8 nM for wild-type and variant, respectively) to nelfinavir. Thermodynamic 
analysis of the protease enzymes indicated that the I36TT mutation does not affect the 
binding energetics of acetyl pepstatin to the protease. Thus, vitality studies suggest that 
the I36TT substitution/insertion mutation and background polymorphisms were 
incorporated in the HIV-1 C-SA protease enzyme to improve viral replication rate. 
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CHAPTER 1 
1 INTRODUCTION 
1.1 Human immunodeficiency virus 
Human immunodeficiency virus (HIV), the causative agent of the acquired immunodeficiency 
syndrome (AIDS), is a retro-virus (an RNA virus) and is the cause of an estimated 1.9 million 
deaths in the world annually (Weiss et al., 1985; Gallo and Montagnier, 1988; WHO, 2008). The 
HI virus mutates rapidly, producing variable strains of the virus within a single host. Based on 
genetic similarities, the HI virus has been categorised into types, groups, and subtypes.  HIV-1 is 
the most prevalent of the two types of HIV (HIV-1 and HIV-2) and is further classified into four 
groups (M, N, O and P). Of the four groups, the Major (M) group of HIV-1 is the most common 
and it is responsible for more than 90% of HIV infections globally.  The “M” group is sub-
divided into ten genetically distinct subtypes (A to H, J and K) (Robertson et al., 2000; Gonzales 
et al., 2001; Velazquez-Campoy et al., 2003). Although the B subtype was the first to be studied, 
as the HIV pandemic continues, more studies are focusing on subtype C since this subtype 
accounts for more than 56% of all new infections globally (Esparza and Bhamarapravati, 2000). 
The higher level of viral fitness and easy transmission of the C-subtype has been proposed to be 
responsible for its increased spread (Gordon et al., 2003; de Oliveira et al., 2003). 
 
1.2 Structure of the HI virus 
The HI virus, like most retroviruses, has three main genes; specifically, gag, pol and env which 
are expressed as zymogens (inactive polyprotein precursors) (Coffin, 1984; Luban et al., 1993). 
The zymogens are later hydrolyzed at specific sites to yield mature structural and functional 
proteins crucial for viral assembly and maturation, and continued infection of the virus       
(Vogt, 1996; Louis et al., 1999; Turner and Summers, 1999) (see Figure 1 for protease cleavage 
sites in the gag-pol polyprotein and the products thereof). Proteolysis of the gag region gives rise 
to the structural proteins; N-terminal matrix protein (p17), the capsid protein (p24), the  
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Figure 1: Structural arrangement of the gag-pol polyprotein precursor in HIV-1  
Specific and additional novel viral protease cleavage sites are indicated by straight arrows and 
asterisks, respectively. The focused region depicts amino acids spanning the NC-TFP, TFP-6pol 
and p6pol-PR junctions. The transframe region (TFR) consists of the transframe octapeptide 
TFP, 48 amino acids of p6pol and an inhibitor of the protease (i.e., the underlined Glu-Asp-Leu 
tripeptide). Bracketed arrows indicate the N-termini of the protease precursor (TFP-p6pol-PR), 
the intermediate p6pol-PR and the mature protease. Figure adapted from Louis et al., 1999. 
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nucleocapsid (p7) and the C-terminal p6 (Luban et al., 1993). The two envelope glycoproteins, 
gp41 and gpl20, in the golgi apparatus are encoded in the env gene and are processed in the final 
stages of HIV-1 life-cycle to produce infectious virion particles (Debouck et al., 1987;           
Niu, 2008). HIV-1 pol gene processing yields three viral enzymes; namely, the protease (p10), 
reverse transcriptase (p66 and p51) and integrase (p32) crucial for viral maturation and 
propagation (Figure 2 summarises the contribution of these proteins in the HIV life-cycle). 
Maturation of the polyproteins is achieved by proteolytic processing of the genes by the protease 
enzyme, encoded in the pol gene of the retrovirus, during late stages of virion formation (Coffin, 
1984; Debouck et al., 1987).  
 
1.3 HIV-1 protease structure and function 
Contrary to other cellular proteases, retroviral proteases (HIV-1 protease included) are 
symmetric homodimers with their substrate binding clefts formed along the interface of the 
dimer (Katoh et al., 1989; Louis et al., 1999). HIV-1 protease is composed of 198 amino acids 
(99 from each subunit) and classified under the aspartic proteinases (Richards et al., 1989; Dash 
and Rao, 2001; Trylska et al., 2007). The formation of the protease dimer is stabilized by the 
conserved intra-monomer contact between Asp29 and Arg87 residues and the active site inter-
monomer contact between Asp25 and Thr26 residues (Ishima et al., 2007). Interface interactions 
between the N-terminal (amino acid 1 to 4) and C-terminal (amino acids 96 to 99) residues     
(see Figure 3) also play a fundamental role in dimer formation (Weber, 1990). Studies have 
indicated that dimer stability is also influenced by the sequences flanking the N-terminus (native 
transframe region) of protease domain in the gag-pol precursor (Louis et al., 1999;             
Ishima et al., 2007). The above observation was indicated by a drastic reduction of the catalytic 
activity of the protease prior to its maturation at the N-terminus. The active site of the HI viral 
protease is covered by “flaps” (flexible β-hairpins formed by residues 45 to 55 of each monomer) 
which control access to the active site (Trylska et al., 2007) (Figure 3). Flexibility of the “flaps” 
is suppressed when the protease is bound to an inhibitor or substrate (Ishima et al., 1999;       
Trylska et al., 2007).  
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Figure 2: HIV life-cycle 
Production of mature and infectious HI viral particles is achieved through synergistic 
contribution of the gag-pol gene products as depicted above. Picture taken from AIDSinfo.org. 
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Figure 3: Ribbon representation of a ligand-bound homodimeric HIV-1 protease 
 The active site of the enzyme is formed from subunit A (in blue) and subunit B (in pink) with 
the two catalytic aspartic acid residues 25 and 25', one from each subunit, shown in red stick-
format at the bottom of the cavity. Dimer formation is stabilised by interface interactions 
between the  N-terminal (amino acid 1 to 4) and C-terminal (amino acids 96 to 99) residues. The 
above structure was generated using Swiss-pdb viewer (Guex et al., 1995). The PDB code used 
to generate this structure is 2R8N. 
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Based on the mechanisms they use to catalyse peptide hydrolysis, protease enzymes are divided 
into two classes. The first class uses an activated nucleophilic (can either be a hydroxy group or 
thiol) atom of an amino acid side chain to initiate hydrolysis of the amide bond carbonyl carbon 
of the substrate’s scissile bond. The second class uses an activated water molecule to attack the 
carbonyl carbon of the scissile amide bond. In the former class, the activated nucleophilic atom, 
activated by another amino acid side chain, attacks the amide bond carbonyl of the substrate’s 
scissile bond to yield an acyl enzyme intermediate (an ester or a thioester). The intermediate is 
then hydrolysed by a water molecule to yield final products. In the latter class, the water 
molecule is activated by either a zinc cation (the zinc metallo-proteases) or by an aspartic acid 
residue, Asp-COO-(Figure 3) (the aspartyl proteases) at the active site. Aspartyl proteases have a 
conserved Asp-Thr-Gly motif within the active site/substrate binding cleft, located at positions 
25 to 27 within the HIV-1 protease, which is implicated in the activity of the HIV protease 
(Miller et al., 1989; Dash and Rao, 2001). Figure 4 summarizes the catalytic mechanism of 
aspartyl proteases, HIV-1 protease included. 
 
 
Okimoto et al. (2000) demonstrated that HIV-1 protease hydrolysis mechanism consists of three 
crucial reactions; namely, the reaction of the formation of the amide hydrate intermediate, the 
reaction of the protonation of the proline nitrogen of the substrate and the reaction of the C-N 
bond cleavage of the substrate. The second reaction being the rate-limiting step because of the 
presence of proline in the amide hydrate intermediate, meaning that proline would cause the 
streric hindrance for the protonation reaction. Studies have demonstrated that replacing the 
catalytic Asp25 residue with an asparagine residue leads to inability of the HIV-1 protease to 
cleave its substrate (Debouck et al., 1987; Seelmeier et al., 1988) and reduced stability of the 
protein during folding (Ishima et al., 2007). 
 
Biochemical and genetic characterization of the HIV genome revealed that viral genomes with 
malfunctioning protease yield immature and noninfectious virion particles, rendering the virus 
harmless (Debouck et al., 1987; Kohl et al., 1988). For this crucial role played by the protease in 
the HIV-1  life-cycle, extensive studies are continuously conducted to design drugs that will bind 
to the active site of the protease enzyme and inhibit it.  
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Figure 4: Mechanism of peptide bond hydrolysis by aspartic protease 
Two aspartic acid residues are located on opposite sides of the peptide bond to be catalyzed in 
the protease active site. One aspartic acid residue (Asp-COO-) acts as general base to activate the 
water molecule (H-OH) which will in turn attack the carbonyl carbon of the scissile amide bond 
of the substrate.  The second aspartic acid residue (Asp-COOH) acts as general acid to protonate 
the leaving amine product. Adapted from Walsh, 2003. 
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1.4 HIV therapy and drug resistant mutations 
Studying and understanding the structure and life-cycle of the HI virus led to development of 
potential drugs that target specific viral proteins. HIV treatment employs drugs that inhibit the 
catalytic properties of the major enzymes (protease, integrase, and reverse transcriptase) which 
the HI virus uses for its continued infection. The regimen is termed HAART and uses a 
combination of drugs (e.g., protease inhibitors, integrase inhibitors and reverse transcriptase 
inhibitors) which suppress viral multiplication and ultimately, improve the host’s immune 
response. Studies have revealed that inhibition of the viral protease offers major therapeutic 
benefits in the battle against HIV (Debouck and Metcalf, 1990) since the enzyme plays a crucial 
role in the viral life-cycle. A large number of currently used antiviral drugs target and inhibit the 
catalytic activities of this viral enzyme. However, effective treatment of HIV-1 infected patients 
is often hindered by the rapid emergence of drug-resistant mutants with reduced susceptibility to 
inhibition by antiretroviral drugs used in HIV-1 treatment (Condra et al., 1995; Schinazi et al., 
1997; Lorenzi et al., 1999; Rodriguez-Barrios and Gago, 2004).  
 
 
Drug resistant mutations arise as a result of high viral replication rate, lack of post-transcriptional 
modification (i.e., proof-reading) of the RT, and poor patient compliance to ARV treatment, 
amongst others (Kantor et al., 2004, Wensing et al., 2005; Cozzi-Lepri et al., 2007). In some 
cases, drug resistant mutations have also demonstrated to be partly accounted for by transmission 
of the infection from drug-experienced patients to uninfected individuals (Wensing et al., 2005). 
Additionally, Gulnik et al. (1995) also showed the possibilities of emergence of cross resistance 
to other protease inhibitors from exposure to just one drug. The structure-based drug design 
combines computational biochemistry and structural biochemical methods to develop new lead 
compounds.  The lead compounds are designed in a way that they have improved potency and 
specificity towards the targeted protein (Wlodawer and Vondrasek, 1998). Thus, second 
generation inhibitors (Figure 5) of the HIV-1 protease were designed (by optimizing favorable 
polar interactions with main chain atoms and to conserved residues, and by reducing the size of 
the inhibitor’s hydrophobic groups) to overcome resistance (Kovalevsky et al., 2006). 
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Figure 5: Chemical structures of the HIV-1 protease inhibitors 
The first generation inhibitors (Indinavir, Saquinavir, Nelfinavir and Ritonavir) of HIV PR were amongst the first drugs developed 
using structure-based drug design. The second generation inhibitors (KNI-764 and KNI-272) were designed to overcome resistance 
due to DR mutations arising from exposure to the first generation inhibitors.  The second generation inhibitors bind to the active site 
with improved specificity. The PIs bind at the active site of the PR. Picture taken from Velazquez-Campoy et al., 2001b. 
10 
 
DR mutations are characterized by amino acid substitutions, deletions, and/or insertions in the 
viral sequence. These mutations frequently emerge in the reverse transcriptase and protease 
enzyme of the HI virus. Studies have revealed that such mutations may alter the viral structure 
and can affect the functional kinetics of the enzyme (Debouck et al., 1987; Kim et al., 2001; 
Ishima et al., 2007). 
 
1.5 Insertion mutations 
Amino acid insertions are a common feature of the reverse transcriptase enzyme of HIV and are 
implicated in the development of drug resistance in HIV positive patients on RT inhibitors (Kim 
et al., 2001; Masquilier et al., 2001; Kozisek et al., 2008). However, in rare cases, insertion 
mutations have also been detected in the protease gene of HIV. In 2001, Kim et al. estimated the 
prevalence of insertions in the protease to be 0.09% from a database of more than 24 000 
genotyped patients’ sera. Most of the insertions in the protease are usually duplications of 
neighboring sequences and are likely generated by RT slippage during reverse transcription 
process (Winters and Merigan, 2001; Kozisek et al., 2008). Part of the “hinge” region (i.e., 
codons 32 to 41, see Figure 3), which leads to the “flaps”, in the protease, is most prone to 
insertions. Mutations in this region cause conformational changes in the active site of the enzyme 
and lead to compromised flap movement (Todd and Freire, 1999). This confers the virus an 
effective way to block access of protease inhibitors to the active site. Consequently, the protease 
develops resistance towards PIs and enhances viral fitness (Kim et al., 2001; Kozisek et al., 
2008). 
 
Following Grant’s report on the possibility of transmitting insert-containing viral strains between 
patients (Grant et al., 2001), Sturmer et al. (2003) reported on a patient with amino acid inserts 
near codon 36 (M36TNL) of the protease prior to protease inhibitor therapy.  This suggested that 
viral strains with inserts in the protease enzyme, with acquired PI resistant mutations, may 
become more common in the future. 
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1.6 Objectives 
Insertion mutations have been detected at various positions in the protease coding region of HIV, 
but codons 32 to 41 of the protease enzyme appear to be more prone to amino acid insertions 
(Winters et al., 2005). Grant et al. (2001) reported on the possibility of transmission of the insert-
containing HI virus amongst patients, suggesting that viral strains with insertion mutations in the 
protease enzyme, that have acquired protease inhibitor resistance, might be more common in the 
future. Later on, amino acid insertions (M36TNL) in the protease sequence of HIV-1 were 
detected in protease inhibitor-naïve patients (Sturmer et al., 2003). The M36TNL variant was 
discovered in the subtype B HIV-1 protease and did not show major effects on the biochemical 
characteristics of the protease enzyme. 
 
Thus, in this study, an HIV-1 South African subtype C protease with an amino acid substituted 
and inserted at codon 36 (I36TT) was assessed (see Figure 6 for the location of the insertion and 
background amino acids polymorphisms). The protease variant was selected from 240 genotyped 
patients’ samples. The PR sequence was obtained from Prof. Lynn Morris (NICD, Johannesburg, 
South Africa). The variant has distinct background polymorphisms (P39S, D60E, and Q61E) 
which accompany the insertion. The protease variant in the current study (I36TT) was detected 
in drug-naïve patients. 
  
The current study was aimed at assessing the contribution of the I36TT substitution/insertion 
mutation to the overall structure and enzymatic properties of the South African HIV-1 subtype C 
protease. Position 36 of the protease is located in the hinge region (Figure 6) which controls 
access to the active site of the enzyme. Mutations in this region may alter protease flexibility and 
activity (Kozisek et al., 2008). Secondary and tertiary structural content of the I36TT variant 
protease were probed using far-UV circular dichroism spectroscopy and intrinsic tryptophan 
fluorescence spectroscopy, respectively. Isothermal titration calorimetric experiments with the 
aspartyl protease inhibitor, acetyl pepstatin, were carried out to evaluate binding energetics of the 
inhibitor to the HIV-1 C-SA protease. Kinetic parameters of the enzyme were evaluated using a 
chromogenic HIV-1 substrate which resembles the protease cleavage site in the gag-pol  
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Figure 6: Ribbon representation of the crystal structure of a free (unbound) conformation 
of HIV-1 protease 
Locations of amino acid residues which are mutated (background polymorphisms) in the I36TT 
variant used in this study are highlighted with spheres of various colors. Shown in green, pink 
and yellow are the α-helices, β-strands and aperiodical structures, respectively. The backbone 
and side chains of the tryptophan residues from each subunit are highlighted in blue stick-format. 
The above structure was generated using Swiss-pdb Viewer (Guex et al., 1995) (PDB code: 
1HHP). 
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polyprotein precursor. Furthermore, inhibition assays were performed using four protease 
inhibitors which are available in our laboratory; notably, saquinavir, indinavir, ritonavir and 
nelfinavir. These drugs are currently employed in HIV therapy. The variant HIV-1 C-SA 
protease was compared to the wild-type protease. 
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CHAPTER 2 
2 MATERIALS AND EXPERIMENTAL PROTOCOLS  
2.1 HIV-1 expression vector 
The pET-11b plasmid carrying a gene encoding subtype B protease was a gift from Dr. Jordan 
Tang from the University of Oklahoma Health Sciences Center, Oklahoma city. The plasmid 
DNA was mutated to code for the wild-type HIV-1 South African subtype C protease by Dr. 
Salerwe Mosebi at the University of the Witwatersrand, Johannesburg, South Africa. 
Autocatalysis of the protease was minimized by introducing the Q7K substitution which reduces 
the most autocatalytic site (Mildner et al., 1994; Velazquez-Campoy et al., 2001a). The plasmid  
is 5.7 kb and is under control of a T7 promoter. Plasmid identity was confirmed by DNA 
digestion using specific restriction enzymes, i.e., BamHI and NdeI, and then analyzed on a 1% 
agarose gel. The cDNA sequence was verified by sequencing (at Inqaba Biotechnical Industries) 
using the universal T7 primer.  
 
2.2 Reagents 
Chromogenic HIV substrate was purchased from California Peptide Research, Inc. California, 
USA. FlexiPrep kit for DNA purification was purchased from Amersham Biosciences, New 
Jersey, USA. Oligonucleotide primers, DNA and protein ladders, and restriction enzymes 
(BamHI and NdeI) were purchased from Inqaba Biotechnical Industries, Pretoria, RSA. The 
QuikChangeTM site-directed mutagenesis kit was purchased from Stratagene, California, USA. 
All other chemicals were of analytical grade. 
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2.3 HIV-1 South African subtype C variant protease sequence  
Sequence data of a patient infected with South African subtype C (C-SA) HIV-1 was obtained 
from Prof. Lynn Morris’s laboratory at the National Institute for Communicable Diseases, 
Johannesburg, South Africa. Viral RNA was purified from the patient’s serum using QIAmp 
MinElute® Spin Kit (QIAGEN) according to the manufacturer instructions. The extracted viral 
RNA was reverse transcribed to synthesize a cDNA which was then amplified with a nested 
PCR. Amplification of cDNA was verified on an agarose gel (1%) containing ethidium bromide. 
PCR product was purified using Roche PCR purification (Roche) according to the manufacturer 
instructions and purity was confirmed using 1% agarose gel with ethidium bromide. DNA was 
further quantitated using a nanodrop spectrophotometer (Thermo Scientific). The pure cDNA 
was sequenced using BigDye Terminator v3.1 Cycle Sequencing Ready Reaction Kit (Applied 
Biosystems) on a PRISM 3100 Genetic Analyzer (Applied Biosystems). Analysis of the resultant 
sequence was performed using Sequencher software program. The protease coding sequence 
contained a single amino acid substitution and insertion at codon 36, i.e., I36TT, and three 
background mutations; notably, P39S, D60E, and Q61E, as compared to the wild-type           
HIV-1 C-SA protease. The above-mentioned mutations were incorporated into the wild-type    
C-SA protease using site-directed mutagenesis to generate the variant protease.  
 
2.4 Generation of variant plasmid DNA 
2.4.1 Mutagenic primer design 
 
Mutagenic primers were designed to incorporate specific oligonucleotides at defined positions 
(see Figure 6) on the wild-type protease sequence to produce the variant protease. The primers 
were designed based on the HIV-1 C-SA protease sequence by Mosebi et al., (2008) with the aid 
of Gene Runner software (v3.01). The oligonucleotide primers used to generate the HIV-1 C-SA 
variant protease incorporating an ATC to ACA ACA (I36TT) substitution/insertion plus the 
background (CCG to TCA (P39S), GAT to GAG (D60E), CAG to GAA (Q61E)) mutations had 
the following sequences (Table 1):  
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Table 1: Primer sequences 
Sequences of primers used to incorporate the I36TT substitution/insertion mutation including background polymorphisms in the HIV-
1 C-SA protease to generate the I36TT variant protease 
 
Mutation Primer Sequence 
D60E/Q61E Forward 5' GTTCGTCAGTATGAGGAAATCCTGATCGAAATCTGCGG 3' 
Reverse 5' CCGCAGATTTCGATCAGGATTTCCTCATACTGACGAAC 3' 
I36TT/P39S Forward 5' GTTCTGGAAGAAACAACAAATCTGTCAGGTAAATGGAAGCC 3' 
reverse 5' GGCTTCCATTTACCTGACAGATTTGTTGTTTCTTCCAGAAC 3' 
Inserted and substituted bases are shown in blue and red, respectively. 
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2.4.2 Generation of the I36TT substitution/insertion and the background 
polymorphisms 
A cDNA, incorporated in pET-11b expression vector, encoding the wild-type HIV-1 South 
African subtype C specific viral mutations was used as a template to generate the variant 
protease. The I36TT substitution/insertion mutation plus the background mutations were 
introduced at specific positions of the plasmid using mutagenic oligonucleotides and a 
QuikChangeTM site-directed mutagenesis kit from Stratagene (Papworth et al., 1996). PCR-based 
site-directed mutagenesis was performed according to the manufacturer’s instructions. Briefly, 
PCR reactions contained 5 µℓ of 10 X reaction buffer, 50 ng of  double-stranded DNA template, 
125 ng of each (forward and reverse) oligonucleotide primers, 10 mM dNTP mix, 1 µℓ PfuTurbo 
DNA polymerase and distilled water added to a total volume of 50 µℓ. Mutagenesis was 
achieved through eighteen amplification cycles at three different temperatures. Amplification 
was performed at 95 °C for 30 seconds to denature the DNA, at 55 °C for 30 seconds to anneal 
the primers to the template DNA strand and at 68 °C for 120 seconds to polymerize the DNA. 
The PCR product was treated with 1 µℓ of the DpnI restriction enzyme to digest the methylated 
and hemimethylated DNA template. The Dpn I-treated DNA was then used to transform 
Escherichia coli XL1-Blue supercompetent cells supplied with the kit    (Chung et al., 1989). See 
Table 2 for a summary of the PCR reaction parameters. 
 
Cells were plated onto lysogeny broth (LB) agar plates supplemented with 100 µg/mℓ of 
ampicillin. Transformants were selected by plating the cells on LB plates supplemented with  
100 µg/mℓ of ampicillin and incubated at 37 °C for 18 hours. Subsequently, the mutant plasmid 
DNA encoded in the pET-11b vector was extracted from the transformed Escherichia coli    
XL1-Blue cells and purified using the FlexiPrep kit as per manufacturer’s instructions. To make 
sure that the correct base substitutions and the insertion have been incorporated, and that no other 
alterations were made during PCR amplification, the purified plasmid DNA was sent to Inqaba 
Biotechnical Industries (Pretoria, RSA) for sequencing. 
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Table 2: PCR cycling parameters 
The I36TT variant was generated using the aforementioned mutagenic oligonucleotides and Stratagene QuikChangeTM site-directed 
mutagenesis kit using PCR under the following conditions: 
 
Segment Cycles Temperature (°C) Time (sec) 
1 1 95 30 
2 18 95 30 
  55 60 
  68 120 
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2.5 Transformation of Escherichia coli cells with plasmid DNA 
Escherichia coli BL21 (DE3) pLysS cells were transformed with the plasmid DNA encoding the 
wild-type HIV-1 C-SA protease. Transformants were selected by plating the cells on LB agar 
plates supplemented with 100 µg/mℓ of ampicillin and 35 µg/mℓ of chloramphenicol and 
incubated at 37 °C for 18 hours. Cells harboring the plasmid were selected and grown at 37 °C in 
a fresh LB medium supplemented with 100 µg/mℓ of ampicillin and 35 µg/mℓ of 
chloramphenicol. The same was done for the variant (containing the I36TT, P39S, D60E, and 
Q61E mutations) plasmid DNA. The wild-type and the I36TT variant C-SA proteases were over-
expressed, purified from washed inclusion bodies and re-folded as described below.  
 
2.6 Over-expression, extraction and purification of the C-SA 
protease 
Plasmid encoding either variant or wild-type HIV-1 SA subtype C protease (containing the 
mutation Q7K designed to reduce the hypersensitive autolytic site) was expressed as inclusion 
bodies (Ido et al., 1991; Todd et al., 1998) in Escherichia coli BL21 (DE3) pLysS cells. Briefly, 
Escherichia coli cells harboring the plasmid DNA were grown at 37 °C in LB medium 
supplemented with 100 µg/mℓ of ampicillin and 35 µg/mℓ of chloramphenicol. The overnight 
culture was diluted 100-fold into fresh 2 × yeast extract and tryptone powder (YT) medium 
supplemented with ampicillin (100 µg/mℓ) and chloramphenicol (35 µg/mℓ) and grown at 37 °C. 
When the optical density (OD600) of the culture reached 0.4 to 0.5 (after two and half hours), 
over-expression of the HIV-1 C-SA protease was induced by adding isopropyl-β-D-
thiogalactopyranoside (IPTG). Upon binding of IPTG to the lac repressor, which regulates 
transcription, the inhibitor is removed from the operator and transcription proceeds (Chung et al., 
1989). IPTG was added to final concentrations of 0.4 mM and 0.2 mM for the wild-type and the 
variant, respectively. Over-expression of both proteases was allowed to continue for two hours.  
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The cells were pelleted after growth and resuspended in ice-cold extraction buffer (10 mM Tris, 
1mM EDTA, and 1 mM PMSF, pH 8). Following the addition of MgCl2 and DNase I to final 
concentrations of 10 mM and 10 U/µℓ, respectively, the culture medium was stirred on ice until 
the viscosity of the mixture decreased. The cells were then ruptured by sonication and 
centrifuged at 15 000 × g for 30 minutes at 4 °C. The pellet was resuspended in ice-cold 
extraction buffer containing 1% (v/v) of Triton X-100. Cell debris and protease-containing 
inclusion bodies were pelleted by centrifugation at 15 000 × g for 30 minutes at 4 °C. The pellet 
was then resuspended in a freshly prepared solubilisation buffer containing 10 mM Tris, 2 mM 
DTT, 8 M urea, pH 8.0, at room temperature, and centrifuged at 15 000 × g for 30 minutes at    
20 °C.  
 
The protease, in the supernatant, was purified using anion exchange (DEAE) column 
chromatography previously equilibrated with solubilisation buffer. HIV-1 PR has a pI of 9.3 and 
will not bind the DEAE column. Upon elution from the column, the protease was acidified by 
adding formic acid to a final concentration of 25 mM. Precipitation of significant amount of 
contaminating proteins occurred upon acidification. Following an overnight incubation, the 
precipitated contaminants were removed by centrifugation at 15 000 × g for 30 minutes at 4 °C. 
The protease was concentrated to a final volume of ~20 mℓ and stored at 4 °C.  
 
HIV-1 protease was refolded by dialysis into 10 mM formic acid at 4 °C. Subsequently, the 
protease was dialyzed into a buffer containing 10 mM sodium acetate, 1 mM NaCl and 1 mM 
DTT, pH 5.0. The folded protease was then desalted into 10 mM sodium acetate buffer, pH 5.0 
using a PD-10 gel filtration column (Amersham biosciences. NJ, USA) and stored at -20 °C.  
 
2.7 Protein concentration determination 
The concentration of the variant and the wild-type HIV-1 C-SA protease was determined 
spectrophotometrically (using a JASCO V-630 UV-VIS spectrophotometer) using the Beer-
Lambert law: 
                                                                                       Equation 1 
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where A is the absorbance, ε is the molar extinction coefficient at a given wavelength (λ),
 
c is the 
concentration of the absorbing medium, and l  is the pathlength of the light through the medium 
in a cuvette. The concentration of pure HIV-1 C-SA protease was subsequently determined 
spectrophotometrically using an extinction coefficient, E1%, of 11.8 at 280 nm                     
(Polgár et al., 1994). A quartz cuvette of 1 cm path length was used for all spectrophotometer 
readings. The purity and the monomeric molecular weight of the proteases were evaluated as 
described in section 2.8 using 15% SDS-PAGE (Laemmli, 1970).  
 
2.8 Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), the discontinuous 
buffer system described by Laemmli (1970), was used to determine the purity and subunit 
molecular weight of the protein. Briefly, the technique uses SDS, an anionic detergent, to 
denature proteins. Upon binding to and denaturation by SDS, the proteins acquire a rod-like 
shape with an overall negative charge. The charged particles migrate towards the electrode of 
opposite charge (i.e., positive terminus) in an electric field. ß-mercaptoethanol is used in SDS-
PAGE to reduce any inter- and intramolecular disulphide bonds. Thus, proteins are separated on 
the basis of size.  
 
The protein samples were diluted five-fold in 5 × loading buffer (0.5 mM Tris-HCl, pH 6.8,  
20% (v/v) glycerol, 10% (w/v) SDS, 100 mM ß-mercaptoethanol, 0.05% (w/v) bromophenol 
blue) and boiled for five minutes to denature the proteins before loading onto the gel. 
Electrophoresis was performed at 200 volts for 45 minutes using a Bio-Rad system. Electrode 
buffer, pH 8.3, contained 0.192 M glycine, 0.124 M Tris base and 0.5% (w/v) SDS. The sizes of 
the proteins were determined in relation to a set of standard proteins, of known molecular 
weight, electrophoresed under the same denaturing conditions. The protein molecular weight 
markers (Fermentas #SM0431) used were: β-galactosidase (116.0 kDa), bovine serum albumin    
(66.2 kDa), ovalbumin (45.0 kDa), lactate dehydrogenase (35.0 kDa), REase Bsp981 (25.0 kDa), 
β-lactoglobulin (18.4 kDa) and lysozyme (14.4 kDa). Immediately after electrophoresis, the gel 
was stained in a solution containing 0.25% (w/v) Coomasie Brilliant Blue R250 dissolved in 
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50% (v/v) methanol and 10% (v/v) acetic acid for two hours to visualize the separated protein 
bands. The gel was then destained in a solution containing 15% (v/v) acetic acid and 10% (v/v) 
ethanol. 
 
2.9 Purification of the protease inhibitors 
Commercially available protease inhibitors (PI) were purified by Dr Salerwe Mosebi at CSIR, 
South Africa. Four of the HIV protease inhibitors employed in clinical settings were used; 
notably, indinavir, nelfinavir, saquinavir and ritonavir. The active ingredients were extracted 
from the tablets and purified using a semi-preparative C-18 reversed-phase HPLC column 
(Velazquez-Campoy et al., 2001a). The inhibitors were lyophilized and stored as powder 
(indinavir and nelfinavir) and as suspensions in 100% dimethylsulphoxide (DMSO) (saquinavir 
and ritonavir) at -20 °C prior to use (Mosebi et al., 2008).  
 
2.10 Calorimetric assays 
2.10.1 Isothermal titration calorimetry 
An isothermal titration calorimeter (ITC) directly measures the heat evolved or absorbed in 
aqueous solutions as a result of injecting precise amounts of reactants into the sample cell. The 
heat signal is a universal phenomenon of binding reactions in the sample cell. Thus, it is 
applicable to most ligand-macromolecule and macromolecule-macromolecule interactions. The 
isothermal power compensation calorimeter is composed of a sample and a reference cell (see 
Figure 7). Both cells are maintained at a constant temperature throughout the experiment 
(Wiseman et al., 1989). The reference cell is usually filled with buffer alone while the sample 
cell has either the protein or the ligand of interest dissolved in the same buffer as the syringe 
contents. Buffer identity is crucial in order to eliminate the large heats of dilution which may 
result and, consequently, mask the desired observations. 
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Figure 7: Schematic representation of ITC cells 
ITC systems use a cell feedback network to differentially measure and compensate for heat 
produced or absorbed between the sample and reference cell. The two cells (i.e., sample cell and 
reference cell) are mounted in a cylindrical adiabatic environment. During ITC experiment, the 
syringe, in the sample cell, rotates to provide continuous mixing of the reactants. Picture taken 
from MicroCal Inc. 
 
 
Sample cell 
(with syringe) 
Inner jackets Outer shield 
Reference cell 
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During an ITC experiment, the reference cell is supplied with a user-defined amount of power 
and the temperature difference between the sample and the reference cell is measured. The 
variable level of thermal power is supplied to the sample cell in order to drive this temperature 
difference to zero. The raw signal from the ITC experiment represents the thermal power 
supplied to the sample cell. The measured change in instrumental thermal power supplied to the 
sample cell, after addition of a ligand or enzyme, is used to determine the reaction rates (Gomez 
and Freire, 1995; Todd and Gomez, 2001). As the syringe contents are injected into the sample 
cell and the two interact, depending on the nature of the reaction (exothermic or endothermic) the 
ITC supplies power to maintain constant temperature between the sample and the reference cell. 
For a heat consuming interaction (endothermic), a positive deflection is observed. Conversely, if 
the reaction generates heat (exothermic), a negative deflection in thermal power is observed (see 
Figure 8).  
 
Resolvability of the binding parameters from the ITC data depends entirely on the concentration 
of the cell reactant relative to the affinity of the interaction. Hence, the initial concentration of 
the protein and the ligand needs to be taken into consideration and both reactants must be of 
highest purity. Too low or too high cell reactant concentration will result in either a data which 
does not allow for determination of interaction parameters or insufficient information in the   
transition region to resolve the affinity constant (Ka), respectively (Todd and Gomez, 2001). 
Precise measurement of the energy required to maintain temperature of the cell during the 
experiment enables simultaneous determination of all binding parameters i.e., Gibbs free energy, 
change in enthalpy, change in entropy, binding affinity and stoichiometry of binding from one 
ITC experiment. For a strong interaction, ∆G must be large and negative, ∆H must be large and 
negative and ∆S must be large and positive. Determination of HIV-1 C-SA protease active site 
concentration was performed using a high-precision VP-ITC titration calorimeter from MicroCal 
Inc., USA. The enzyme (protease) solution at 20 µM was loaded into the ITC sample cell and 
titrated with the ligand (300 µM) dissolved in the same buffer (10 mM sodium acetate, pH 5.0). 
Acetyl pepstatin, an aspartic protease inhibitor, was used a ligand when determining the 
concentration of the active site of the HIV-1 protease. The heat evolved after each inhibitor 
injection was obtained from the integration of the area under the peak of the heat signal. The heat 
due to the binding reaction between the protease enzyme and the inhibitor was obtained from the  
25 
 
 
 
          
 
      
 
 
 
 
 
 
Figure 8: HIV-1 binding isotherms  
Exothermic (A) and endothermic (B) ITC profiles of the wild-type HIV-1 subtype B protease 
titrated with KNI-764 (in A) and acetyl pepstatin (in B) inhibitors. Figure adapted from 
Velazquez-Campoy et al., 2001b. 
 
 
A B 
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difference between the heat of reaction and the corresponding heat of dilution (dilution of 
inhibitor in a buffer). At the end of the experiment, saturation of the macromolecule is reached 
and it is possible to measure the heats associated with binding events; particularly, ∆H, ∆S, ∆G, 
Ka and N (Velazquez-Campoy et al., 2001b). The independent variables; Ka, N and ∆H were 
directly determined from the integrated heat signal. The ∆G of binding was calculated by 
substituting the value of Ka in the equation: 
 
∆   
    Equation 2 
 
where R is the universal gas constant (1.98 cal.mol-1.K-1) and T is the temperature in Kelvin. ∆S 
was in turn calculated using the equation:  
 
∆  ∆ 
  ∆     Equation 3 
 
 
The stoichiometry obtained from the titration data is then used to estimate the concentration of 
active site in the protease molecule. A stoichiometry of 1 corresponds to a 100% active site 
concentration. 
 
2.11 Protease characterization 
2.11.1 Structural assessment 
2.11.1.1  Secondary structure 
Circular dichroism (CD) is observed when optically active matter absorbs left and right handed 
circularly polarized light differently. To generate a CD signal, the optically active molecule 
(chromophore), must either be in an optically asymmetric environment or be intrinsically chiral 
(Pain, 2004). The chromophores in proteins are the aromatic acid residues, peptide backbone and 
disulphide bonds (Woody, 1995). CD signal is generated during the transition of an electron 
from a filled ground state orbital (n or π) to an empty excited state orbital (π*) with higher 
energy. The raw CD signal is expressed in terms of ellipticity (θ) given as: 
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  .        Equation 4 
 
where AL and AR are the absorbances of the left- and right-handed circularly polarised light 
(Modi et al., 1993). The raw CD signal (θ) was buffer-corrected then converted to mean residue 
ellipticity (deg.cm2.dmol-1) using the equation: 
 
          Equation 5 
 
where θ is the raw signal (mdeg), c is the concentration of the protein (mM), n is the number of 
residues in the protein and l is the path length of the cuvette (cm) (Woody, 1995). 
 
The technique is used for assessing the structures of proteins and peptides in solution and was 
employed in this study to determine structural properties of both the wild-type and the variant 
HIV-1 C-SA protease. Secondary structures were determined using far-UV (250 to 190 nm) CD 
spectra due to light absorption by the peptide backbone (Adler et al., 1973). The data were taken 
on a Jasco J-810 spectropolarimeter, constantly flushed with nitrogen to remove oxygen, using a 
2 mm path length quartz cuvette. The spectropolarimeter was set at 20 °C and the data were 
collected under the following conditions: 0.1 nm data pitch, 0.1 nm bandwidth, and 50 nm.min-1 
scan speed. 
 
2.11.1.2 Tertiary structure 
Fluorescence is an emission phenomenon which involves energy transition from higher to lower 
state. Briefly, molecules in their lower energy state are excited by the absorption of light of a 
specific wavelength to a higher energy state. The excited molecules return to ground state at 
longer wavelength than the excitation radiation and the energy emitted is manifested as 
fluorescence (van Holde et al., 1998). Energy loss is rapid (as heat) and occurs by collision 
degradation. This loss of energy between absorbed and emitted light is known as “Stokes’ shift”. 
(Lakowicz, 1999). The aromatic compounds (with delocalised π-electrons) are most easily 
excited to higher energy states, and thus are prone to fluoresce. Proteins exhibit characteristic 
fluorescence spectra according to the environment within which the main fluorescing species are 
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packed. The greater the exposure of Trp to the polar aqueous environment, the longer its 
wavelength of maximum emission will be, since the polar solvent molecules lower the energy of 
the excited state (Royer, 1995). Tyr fluorescence is almost totally quenched if it is ionised or 
near an amino group, or carboxylic group or Trp.   
 
Fluorescence spectroscopic assays were used to investigate the localized conformational changes 
induced in the tertiary structure of the protease. Changes occurring in the tertiary structure of the 
protease were monitored using the intrinsic fluorescence of the phenyl and indole rings of 
tyrosine and tryptophan, respectively, as probes. Tyr and Trp were excited at 280 nm, and 
tryptophan was selectively excited at 295 nm (Shirley 1995). C-SA protease has two tryptophan 
residues (located at positions 6 and 42, see Figure 6) per subunit. These tryptophans are located 
where they will not detect major/global structural changes and are quite exposed to the solvent; 
therefore, they were used to monitor local structural changes. Fluorescence assays were 
performed using a PerkinElmer LS 50 B Luminescence fluorimeter. Fluorescence emission was 
monitored between 290 and 550 nm. Excitation and emission slits were set at 4.0 nm and 3.5 nm, 
respectively. The scan speed was set at 350 nm.min-1 and ten accumulated scans were averaged 
for each spectrum. The assays were conducted using 5 µM protein in 10 mM sodium acetate 
buffer, pH 5.0.  
 
2.11.2  Spectrophotometric analyses 
2.11.2.1 Protease enzyme kinetics 
Enzymatic activity of the HIV-1 C-SA protease was measured by following the hydrolysis of the 
HIV chromogenic substrate, Lys-Ala-Arg-Val-Nle-nPhe-Glu-Ala-Nle-NH2. The substrate 
resembles the conserved protease cleavage site, KARVL/AEAM, between the capsid protein and 
the nucleocapsid p2 in the Gag-polyprotein precursor (Velazquez-Campoy et al., 2001a). 
Hydrolysis of the HIV chromogenic substrate was characterised by the decrease in absorbance         
at 300 nm. Catalytic properties such as the KM, Vmax, kcat, and kcat/KM of the proteases were 
determined (Velazquez-Campoy et al., 2001a and Mosebi et al., 2008). All catalytic activity 
assays were performed using a Jasco V-630 spectrophotometer.    
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The KM for the substrate was calculated based on different catalytic activities measured using 
constant concentration of the protease and varied substrate concentrations. Initial reaction 
velocities were plotted against substrate concentrations in order to generate Michaelis-Menten 
plots. Thus, KM and Vmax values were determined by fitting the data in the following equation:  
 
!  !"# $%$%&                 Equation 6 
 
where V0 is the initial velocity of the reaction, Vmax is maximum velocity attained by the reaction, 
and [S0] is the substrate concentration in the reaction (when substrate concentration is much 
greater than enzyme concentration).  
 
Protease was added to a micro-cuvette containing substrate at 20 °C. Final concentrations for the 
KM and Vmax determination assays were: 300 nM protease, 100 µM substrate, and 10 mM sodium 
acetate buffer, 0.1 M NaCl, pH 5.0.  
 
It is known that when the substrate concentration is very high, all the enzyme is present as the 
enzyme-substrate complex, and the limiting initial velocity, Vmax, is reached. Under such 
conditions, the turnover number was determined from the slope of the linear plot of catalytic 
activity versus enzyme concentration using the equation: 
 !"#  '($%)    Equation 7 
 
where [E]t is the total protease concentration in the assay.  
 
When the substrate concentration is very low, there is a linear relationship between V0 and [S0], 
since [S0] « KM, then ([S0] + KM) ≈ KM. Hence, the catalytic efficiency of the protease was 
calculated as the slope of the linear plot of catalytic activity against substrate concentration using 
the following equation: 
 
!  *'( + $,%)     Equation 8 
The measured slopes of the plots were then divided by the respective enzyme concentrations to 
give values for kcat/KM. 
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2.11.2.2 Inhibition studies 
The concentration of the individual protease inhibitors needed to reduce the catalytic activity of 
the HIV-1 C-SA protease enzyme by 50% (IC50 value) was determined at 25 °C by measuring 
the rate of chromogenic substrate hydrolysis in the presence of various protease inhibitors. 
Standard assays containing 300 nM protein and saturating concentration (i.e., 250 µM) of 
chromogenic substrate were performed in the presence of increasing concentrations of inhibitor. 
Separate assays were performed for each of the following protease inhibitors currently in clinical 
use; i.e., saquinavir, ritonavir, indinavir, and nelfinavir. 
  
2.12 Data analysis 
Protease concentrations used are for dimeric protein unless otherwise stated. The terms mutant 
and variant are used interchangeably in this dissertation. Data fitting was performed using Sigma 
Plot v11.0 software (Systat softwares) unless stated otherwise. ITC data was fitted using ITCone 
from ORIGIN v5.0 software (MicroCal. Inc.). All HIV-1 protease structures were generated 
using Swiss PDB viewer software (Guex et al., 1995).  
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CHAPTER 3 
3 RESULTS 
3.1 Plasmid DNA sequence confirmation 
cDNA encoding wild-type HIV-1 South African subtype C protease was used as a template 
during PCR-based site-directed mutagenesis to generate the variant cDNA. The cDNA encoded 
in the pET-11b plasmid was purified and sequenced using the Universal T7 primer. DNA 
sequencing was performed (at Inqaba Biotechnical Industries) in order  to confirm that only the 
mutations observed in the I36TT variant had been incorporated in the protease sequence, and no 
other alterations had occurred during amplification. Sequencing (Figure 9A) and sequence 
alignment results (Figure 9B) revealed that only the I36TT (ATC to ACA ACA) 
substitution/insertion and its accompanying polymorphisms (CCG to TCA (P39S), GAT to GAG 
(D60E), CAG to GAA (Q61E)) were incorporated. The variant protease sequence was aligned 
with the wild-type HIV-1 C-SA protease to highlight differences between the two proteases 
(Figure 9B) and it showed that the variant protease has 100 amino acids in its sequence in 
contrast to the wild-type with only 99 amino acids.  
 
3.2 Protease purity and monomeric molecular weight 
determination 
Following over expression of the HIV-1 C-SA protease and its subsequent extraction and 
purification from inclusion bodies, protease purity and subunit molecular weight were 
determined using SDS-PAGE (Figure 10A). Electrophoresis results revealed that the wild-type 
and the mutant protease were pure. This was indicated by a single band observed in the lane in 
which the protein was loaded in the gel. Using the electrophoresis gel (Figure 10A), the 
calibration curve of logarithm of the molecular weight of the protein molecular weight markers 
versus the distance migrated by individual proteins was plotted. The monomeric molecular  
 
 A 
B 
Wild-type     PQITLWKRPLVSIKVGGQIKEALLDTGADDTVLEE
I36TT Variant PQITLWKRPLVSIKVGGQIKEALLDTGADDTVLEE
              ***********************************
 
Wild-type     IGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF 99
I36TT Variant IGGFIKVRQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF 100
              **********::**************************************
 
 
Figure 9: Variant protease sequence 
(A) Sections of the chromatograms highlighting four codons
codon number 36 (I36TT) of the 
protease. The background mutations accompanying the insertion/mutation are hig
codons 39 (P to S), 60 (D to E), and 61 (Q to E) of the HIV
Alignment of the wild-type and the variant HIV
indicating differences and similarities between the two protea
(reduces autocatalysis of the protease enzyme) was also incorporated and is highlighted in pink. 
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Figure 10: HIV-1 C-SA protease purity and molecular weight determination 
(A) 15% SDS-PAGE gel and (B) calibration curve for determination of the molecular weight of 
the monomeric HIV-1 C-SA proteases. Lanes 1, 2 and 3 represent the purified wild-type 
protease, protein molecular weight marker, and purified variant protease, respectively. The 
protein molecular weight markers used were: β-galactosidase (116.0 kDa), bovine serum 
albumin (66.2 kDa), ovalbumin (45.0 kDa), lactate dehydrogenase (35.0 kDa), REase Bsp981 
(25.0 kDa), β-lactoglobulin (18.4 kDa), and lysozyme (14.4 kDa). Wild-type and variant HIV-1 
C-SA protease both migrated a distance corresponding to a size of 11.2 kDa. Position of the 
protease is marked (x). The correlation coefficient is 0.96.  
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weight of the wild-type and the variant HIV-1 C-SA proteases were determined from the 
calibration curve, Figure 10B, by fitting data from the plot to the linear equation (y = mx + c).  
The monomeric molecular weight of the C-SA protease was found to be 11.2 kDa, corresponding 
to the value of the HIV-1 protease previously reported by Ido et al. (1991).  
 
3.3 Protein concentration determination 
The concentration of the purified South African HIV-1 subtype C protease was determined by 
measuring the absorbance of light in the ultra-violet region of the spectrum. Optimum 
absorbance intensity was observed at 280 nm (Figure 11) and was due to the chromophores   
(i.e., aromatic amino acid residues) in the HIV-1 protease. Using the protein absorption 
spectrum, Figure 11, the protease concentration was calculated and it was found to be 20 µM.  
 
3.4 Structural characterization 
3.4.1 Secondary structural content assessment 
Circular dichroism was used in the far-UV range (250 to 190 nm) to probe changes in the 
secondary structure of both the wild-type and the variant protease. Both proteases exhibited far-
UV CD spectra distinctive of a predominantly β-sheeted protein, characterized by a negative 
peak at 216 nm (Figure 12). This was in agreement with the secondary structural content of    
HIV-1 protease as previously reported (Navia et al., 1989; Dash and Rao, 2001; Foulkes et al., 
2006; Mosebi et al., 2008) (Figure 6).  
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Figure 11: HIV-1 C-SA absorption spectrum 
 Absorption spectrum of 20 µM HIV-1 South African subtype C protease. The experiment was 
carried out at 20 °C in 10 mM sodium acetate buffer, 0.1 M sodium chloride,   pH 5.0. The 
spectrum illustrates the absorption of ultra-violet light by the aromatic amino acids’ side chains 
of the protein at 280 nm wavelength. 
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Figure 12: Far-UV CD spectra of HIV-1 C-SA protease 
Representation of the far-UV circular dichroism spectra of the wild-type (in green) and the 
variant (in red) HIV-1 C-SA protease in 1 mM sodium acetate buffer, pH 5.0. The spectra were 
used to assess the secondary structural content of the protease. The data were collected from a 
Jasco J-810 spectropolarimeter using 25 µM protein in 2 mm path length cuvette. The 
experiments were conducted at 20 °C under the following conditions: 0.1 nm data pitch, 0.1 nm 
bandwidth, 250 to 190 nm, and 50 nm.min-1 scan speed. Each spectrum is an average of ten 
scans. 
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3.4.2 Tertiary structure determination 
Changes in the tertiary structure of the protease were monitored using intrinsic fluorescence 
spectroscopy and the four solvent-exposed tryptophan (W6, W6', W42 and W42') residues in the 
protease sequence as probes. Fluorescence spectra (Figure 13) from both excitation wavelengths 
(280 and 295 nm) revealed that the local environment of the tryptophan residues in the variant 
protease had not been perturbed when compared to the wild-type. Both the wild-type and the 
variant proteases exhibited fluorescence emission spectra typical of free tryptophan in solvent, 
with an emission intensity maximum at 355 nm (Lakowicz, 1999).   
 
3.5 Enzymatic characterization 
3.5.1 Catalytic activity studies 
Kinetic parameters of the HIV-1 South African subtype C protease were assessed following 
hydrolysis of chromogenic HIV-1 substrate, mimicking the protease cleavage site in the gag-pol 
protein precursor. The reaction was monitored at 300 nm using an absorbance spectrophotometer 
(Figure 14). Hydrolysis of the substrate was monitored for three minutes for each kinetic assay 
and only the first fifty seconds of the enzyme reaction was considered when measuring catalytic 
activity of the enzyme.  This was considered due to the linear relationship between the reaction 
rate and the initial velocity. Overall enzymatic activity (depicted in Figures 15 to 19 and further 
summarized in Table 3) of the C-SA variant protease is slightly enhanced in the presence of the 
I36TT insertion/mutation and its accompanying background polymorphisms.  
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Figure 13: Intrinsic tryptophan fluorescence emission spectra of the HIV-1 C-SA protease 
(A) The emission spectrum of tryptophan and tyrosine excited at 280 nm. (B) The emission 
spectrum of tryptophan selectively excited at 295 nm. Both proteins fluoresce maximally at 355 
nm at both excitation wavelengths. Fluorescence emission of the wild-type (in green) and the 
variant (in red) HIV-1 C-SA protease in 10 mM sodium acetate buffer, pH 5.0. Each spectrum is 
an average of ten accumulations.  The dashed vertical lines highlight the wavelength at which 
maximum fluorescence emission intensities were attained.  
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Figure 14: Progress curve for HIV-1 substrate hydrolysis 
Progress curve of the HIV-1 South African subtype C protease catalyzing the hydrolysis of the 
synthetic HIV-1 chromogenic substrate. The assay was performed at 20 ° C using 300 nM 
enzyme concentration and 50 µM substrate in 10 mM sodium acetate buffer, 0.1 M sodium 
chloride, pH 5.0. The initial velocity (first 50 seconds of the reaction) considered when 
determining the reaction rate is indicated (---). The assay was monitored at 300 nm. 
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Figure 15: Determination of specific activity  
Specific activity of the wild-type (●) and the variant (○) HIV-1 C-SA proteases. The catalytic 
activities of both enzymes were calculated by monitoring the hydrolysis of the chromogenic 
HIV-1 substrate which was indicated by the decrease in absorbance at 300 nm. The experiment 
was carried out at 20 °C in 10 mM sodium acetate buffer, 0.1 M sodium chloride, pH 5.0, and 
saturating substrate concentration (i.e., 250 µM). The experiments were conducted in triplicates 
and the data is reported as the mean ± SD. Catalytic activity of the protease enzyme was 
calculated by dividing the spectrophotometrically measured absorbance per minute of the 
hydrolyzed substrate by the enzyme’s molar extinction coefficient. The specific activity of the 
protease was calculated from the slope of the plot and was found to be 2.9±0.095 µmol/min/mg 
and 3.1±0.11 µmol/min/mg for wild-type and variant protease enzyme, respectively. The solid 
lines represent linear fits to the experimental data. The correlation coefficient is 0.98 for both the 
wild-type and the mutant.  
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Figure 16: Wild-type protease catalytic constant and maximum velocity determination  
(A) Michaelis-Menten plot and (B) Lineweaver-Burke plot for determination of KM and Vmax of 
the wild-type HIV-1 C-SA protease towards the chromogenic HIV substrate. KM and Vmax values 
were found to be 193.3±35.69 µM and 0.0021±2.34×10-4 µmol.min-1, respectively. The assays 
were carried out at 20 °C in 10 mM sodium acetate buffer, 0.1 M sodium chloride, pH 5.0, and 
300 nM protease enzyme. The solid lines through the data points are hyperbolic and linear fits, 
respectively, to the experimental data. The correlation coefficient for the linear fit is 0.95. The 
experiments were conducted in triplicates and the data is reported as the mean ± SD. 
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Figure 17: Variant protease catalytic constant and maximum velocity determination  
(A) Michaelis-Menten plot and (B) Lineweaver-Burke plot for the determination of KM and Vmax 
of the I36TT variant HIV-1 C-SA protease towards its substrate. KM and Vmax values were found 
to be 89.14±12.12 µM and 0.0017±1.03×10-4 µmol.min-1, respectively. The experiments were 
conducted in triplicates and the data is reported as the mean ± SD. The assays were conducted at 
20 °C in 10 mM sodium acetate buffer, 0.1 M sodium chloride, pH 5.0, and 300 nM enzyme. 
The solid lines represent hyperbolic and linear fits, respectively, to the experimental data. The 
correlation coefficient for the linear fit is 0.96. 
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Figure 18: Determination of enzyme turn-over number  
Linear curves for determining the turn-over number (kcat) of the wild-type (●) and the variant (○) 
HIV-1 C-SA proteases. Turn-over number was determined from the slopes of the plots and was 
found to be 0.10±0.49×10-2 s-1 and 0.18±1.18×10-2 s-1 for wild-type and variant protease, 
respectively. The solid lines through the data points are linear fits to the experimental data. The 
correlation coefficient for the linear fit is 0.96 and 0.92 for the wild-type and mutant, 
respectively. The experiments were performed at 20 °C in 10 mM sodium acetate buffer, 0.1 M 
sodium chloride, pH 5.0, and saturating substrate concentration (i.e., 250 µM). The experiments 
were conducted in triplicates and the data is reported as the mean ± SD. 
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Figure 19: Catalytic efficiency determination  
Linear curves for determining the catalytic efficiencies (kcat/KM) of the wild-type (●) and the 
variant (○) HIV-1 C-SA proteases. Catalytic efficiencies were determined by calculating the 
slopes of the plots and multiplying by the concentration of the enzyme in the assay. kcat/KM 
values were found to be 0.007±6.56×10-5 µM-1.s-1 and 0.011±8.03×10-5 µM-1.s-1 for wild-type and 
variant protease enzyme, respectively. The assays were conducted at 20 °C in 10 mM sodium 
acetate buffer, 0.1 M sodium chloride, pH 5.0, and 300 nM enzyme. The experiments were 
conducted in triplicates and the data is reported as the mean ± SD. The solid lines through the 
data points are linear fits to the experimental data. The correlation coefficient for the linear fit is 
0.95 and 0.98 for the wild-type and the mutant, respectively. 
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Table 3: Summary of the catalytic parameters 
Enzymatic characteristics of the wild-type and the variant HIV-1 C-SA proteases 
 
Parameter Wild-type Variant 
Specific activity (µmol/min/mg) 2.9±0.095 3.1±0.11 
Vmax (µmol.min-1) 0.0021±2.34×10-4 0.0017±1.03×10-4 
KM (µM) 193.3±35.69 89.14±12.12 
kcat (s-1) 0.10±0.49×10-2 0.18±1.18×10-2 
kcat/KM (µM-1.s-1) 0.007±6.56×10-5 0.011±8.03×10-5 
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3.5.2 Inhibition kinetics 
IC50 values of the four clinical protease inhibitors; notably, saquinavir, indinavir, ritonavir and 
nelfinavir, were determined following catalysis of the same chromogenic substrate. The four 
drugs used were the only ones available in our laboratory and are amongst some of those 
prescribed during HIV therapy. Wild-type and variant enzymes did not possess significant 
differences for saquinavir and nelfinavir (Figures 20 and 23). However, variant IC50 values for 
indinavir and ritonavir were increased two-fold relative to the wild-type (Figures 21 and 22). 
Table 4 summarizes figures for IC50 values of the four protease inhibitors for the variant and 
wild-type protease enzymes. IC50 values for all four inhibitors were determined from the 
inhibition percentage versus inhibitor concentration plots. Activity percentages were calculated 
using the following equation: 
 
                                          (-.-(/ %  !12 - 3-4-(56 75(-1 !12 8 - 3-4-(56 75(-1                       Equation 9 
 
 
 where V0 is the enzyme catalyzed reaction rate. 
 
3.6 Thermodynamic characteristics 
Thermodynamic parameters of the wild-type HIV-1 C-SA protease and the I36TT variant 
protease were determined using calorimetric assays. All binding parameters i.e., Gibbs free 
energy, change in enthalpy, change in entropy and binding affinity were obtained (Table 5) and 
did not show any significant differences in thermodynamic parameters between the wild-type 
and the I36TT variant protease. Figure 24 represents an ITC profile obtained from 20 µM HIV-1 
C-SA protease binding to acetyl pepstatin (300 µM).  
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Figure 20: Determination of IC50 value for saquinavir 
Graph used to determine the IC50 value (inhibitor concentration needed to decrease the catalytic 
activity of the enzymes by 50%) of the wild-type (●) and the variant (○) HIV-1 C-SA protease. 
IC50 values for wild-type and mutant were 7.6 nM and 6.3 nM, respectively. The solid lines 
represent exponential decay fits to the experimental data. The experiments were performed at   
20 °C using enzyme concentration of 300 nM, saturating substrate concentration (i.e., 250 µM) 
and increasing saquinavir concentrations in 10 mM sodium acetate buffer, pH 5.0. Inhibition 
percentages were calculated using Equation 9. All experiments were conducted in triplicates and 
the data is reported as the mean ± SD. 
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Figure 21: Indinavir IC50 value determination 
 Plots used to determine the IC50 values of indinavir with the wild-type (●) and the mutant (○) 
HIV-1 C-SA protease enzyme.  IC50 values were 9.5 nM and 16.2 nM for wild-type and mutant 
protease enzymes, respectively. The final concentrations in the assays were: 300 nM enzyme, 
saturating (250 µM) substrate concentration and increasing indinavir concentrations in 10 mM 
sodium acetate buffer, pH 5.0 at 20 °C. All experiments were conducted in triplicates and the 
data is reported as the mean ± SD. The solid lines through the data points are exponential decay 
fits to the experimental data. 
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Figure 22: Ritonavir IC50 value determination 
 IC50 values of ritonavir were determined in the presence of the wild-type (●) and the variant (○) 
HIV-1 C-SA protease enzymes using these plots. IC50 values for wild-type and mutant were  
19.1 nM and 36.4 nM, respectively. The solid lines represent exponential decay fits to the 
experimental data. The assays were performed at 20 °C using 300 nM enzyme concentration, 
saturating substrate concentration (i.e., 250 µM) and increasing ritonavir concentrations in 10 
mM sodium acetate buffer, pH 5.0. All experiments were conducted in triplicates and the data is 
reported as the mean ± SD. 
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Figure 23: Nelfinavir IC50 value determination  
Graph used to determine the inhibitor concentration needed to decrease the catalytic activity of 
the wild-type (●) and the variant (○) HIV-1 C-SA protease enzymes by 50%. (IC50 values).  IC50 
values were 17.3 nM and 16.8 nM for wild-type and mutant protease, respectively. The 
experiments were carried-out using enzyme concentration of 300 nM, saturating (250 µM) 
substrate concentration and increasing nelfinavir concentrations in 10 mM sodium acetate buffer, 
pH 5.0 at 20 ° C. All experiments were conducted in triplicates and the data is reported as the 
mean ± SD. The solid lines through the data points represent exponential decay fits to the 
experimental data. 
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Table 4: Summary of inhibitors IC50 values 
Inhibition characteristics (IC50 values) of the wild-type and the variant HIV-1 C-SA proteases 
 
 
 
IC50 value (nM) 
Saquinavir Indinavir Ritonavir Nelfinavir 
Wild-type 7.6 9.5 19.1 17.3 
Variant  6.3 16.2 36.4 16.8 
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Table 5: Thermodynamic parameters of binding 
Wild-type and variant HIV-1 C-SA PR binding parameters were determined using calorimetric assays and the inhibitor acetyl 
pepstatin 
 
Parameter 
 
Wild-type Variant 
 
∆G (kcal/mol) 
 
-8.0 
 
-8.1 
 
∆H (kcal/mol) 6.2 
 
6.5 
 
-T∆S (kcal/mol) -14.0 -14.6 
 
Kd (nM) 
 
380 395 
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Figure 24: Representation of the HIV-1 C-SA protease binding isotherm 
Isothermal titration calorimetric plot of the I36TT mutant HIV-1 C-SA protease titrated with    
10 µl injections of 300 µM acetyl-pepstatin. Initial enzyme concentration in the ITC sample cell 
was 20 µM in 10 mM sodium acetate buffer, pH 5.0. Acetyl-pepstatin in the ITC syringe was 
also dissolved in the same buffer. The top panel shows the heat trace of the thermostat over the 
time of the experiment with individual injections of the inhibitor as peaks. The lower panel 
shows the integrated area of the peaks plotted against molar ratio of the inhibitor to protease. 
Data fitted using ITCone from ORIGIN v5.0 (MicroCal Inc.). 
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CHAPTER 4 
4 DISCUSSION 
The current study assessed the effects of an amino acid substitution and insertion plus 
background polymorphisms in the overall structure and catalytic ability of HIV-1 C-SA PR. The 
variant plasmid encoding HIV-1 C-SA PR, containing the I36TT amino acid 
substitution/insertion plus background polymorphisms, was generated using site-directed 
mutagenesis and the plasmid encoding the wild-type as a template. DNA sequencing results 
revealed that only the desired mutations were incorporated in the wild-type plasmid to yield 
variant plasmid. The wild-type and variant HIV-1 C-SA PRs were expressed as inclusion bodies 
in Escherichia coli BL21 (DE3) pLysS cells. The variant PR was expressed in higher yields       
(6 mg/mℓ) as compared to the wild-type PR (4 mg/mℓ). Both PRs were purified using a DEAE 
anion exchange column containing an equilibration buffer at pH 8.0.  Both PRs were isolated to 
absolute purity and homogeneity (Figure 10). The above results are in agreement with previously 
determined findings of HIV-1 PR (Ido et al., 1991; Mosebi et al., 2008).  
 
4.1 Structural content assessment 
4.1.1      Secondary structure 
Circular dichroism spectroscopy provides information about differential absorption between left- 
and right-handed circularly polarized light in optically-active media (Lowry, 1935). The 
optically active elements in polypeptides and proteins are the peptide backbone, amide 
interactions (α-helices and β-sheets), and the side chains of aromatic amino acids             
(Woody, 1995). Manning et al. (1988) demonstrated that even small conformational distortions 
in the backbone of a polypeptide or protein can result in strong alterations of the circular 
dichroism signal. Thus, highly sensitive circular dichroism was used in this study to monitor 
conformational changes in the protein backbone. Possible changes in the secondary structural 
content of the variant and the wild-type South African HIV-1 subtype C protease were probed 
using circular dichroism spectroscopy in the far-UV (250 to 190 nm) range. Although equal 
concentrations of the wild-type and the mutant proteins were used, far-UV CD spectra of the 
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variant protein showed a CD signal with 10% reduction in intensity relative to the wild-type 
(Figure 12). The reduced CD signal is correlated to the minor structural (peptide back-bone) 
alterations induced by the mutations in the variant protease. Nonetheless, both the I36TT variant 
and wild-type protease exhibited far-UV CD spectra with minima at 216 nm. The observed 
negative peak at 216 nm is typical of a predominantly β-sheeted polypeptide/protein. This is in 
agreement with previous studies (Navia et al., 1989; Dash and Rao, 2001; Foulkes et al., 2006; 
Mosebi et al., 2008) which characterized the secondary structure of the HIV-1 protease using far-
UV circular dichroism as a probe and reported that the protease is 48% β-sheet, 4% α-helix, and 
48% aperiodic conformation. This can also be confirmed by studying the crystal structure of the 
HIV-1 protease (Figure 6). The negative peak near 220 nm is due to the n-π* transition of the 
peptide backbone and it is very sensitive to conformational alterations occurring in the 
polypeptide chain (Hennessey and Johnson, 1981; Modi et al., 1993). Hence, the secondary 
structural elements of the HIV-1 C-SA protease were not significantly perturbed by the presence 
of I36TT mutation and its background polymorphisms. 
 
4.1.2 Tertiary structure 
Fluorescence spectroscopic assays are sensitive to changes in local environments; hence, 
intrinsic tryptophan fluorescence is employed to investigate the localized conformational 
changes induced in the tertiary structure of the protein. Conformational changes occurring in the 
tertiary structure of the protein are monitored using intrinsic fluorescence of the phenyl and 
indole ring of tyrosine and tryptophan, respectively, as probes (Shirley, 1995). HIV-1 C-SA 
protease has two tryptophan residues, at positions 6 and 42, in each subunit. Thus, possible 
changes induced by the I36TT mutation and its background mutations in the tertiary structure of 
the  HIV-1 C-SA protease were probed using intrinsic tryptophan fluorescence. These tryptophan 
residues are located where they will not detect major/global structural changes (see Figure 6 for 
location of the tryptophan residues in the HIV-1 protease) and are quite exposed to the solvent. 
Therefore, they will be used to monitor only local structural changes.  
 
The fluorescence emission spectra of both Trp and Tyr residues were monitored after excitation 
at 280 nm, and Trp fluorescence was selectively excited at 295 nm (Figures 13 A and B). 
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Although excitation of the variant protein exhibited about 20% enhanced fluorescence emission 
intensity as compared to the wild-type, there were no Stokes’ (red and/or blue) shifts observed 
for both proteins at both excitation wavelengths. Intrinsic tryptophan emission fluorescence 
spectra of the variant and wild-type protease, at both excitation wavelengths (i.e., 280 and       
295 nm) were similar, with maximum intensity at 355 nm. This shows that the tryptophan 
residues in the fully folded native HIV-1 C-SA are highly exposed to the solvent (Figure 6) since 
free tryptophan fluoresces maximally between 350 and 355 nm in water (Lakowicz, 1999). Even 
though both proteins exhibited maximum fluorescence intensities at the same wavelengths, the 
wild-type protein displayed about 20% reduction in fluorescence intensity relative to the mutant. 
The enhanced intensities may be due to the fact that some of the tryptophan energies, which were 
quenched in the wild-type protein are no longer quenched in the variant protein. This suggests 
that there might be some minor alterations induced in the structure of the HIV-1 C-SA protease 
by the I36TT mutation and its background polymorphisms. These findings are in agreement with 
a study (Kozisek et al., 2008) which compared the structures of mutant HIV-1 subtype B 
protease containing a single amino acid insertion each (E35EE and L33LL) to the wild-type, and 
reported that insertion does not significantly change the overall inhibitor binding to the active 
site for both mutant proteins. For this reason, homology modeling and crystal structures of the 
wild-type and the I36TT variant protein can report on the degree of conformational alterations 
induced in the overall structural content of the HIV-1 C-SA protease by the I36TT mutation and 
its background polymorphisms.  
 
4.2 Enzymatic characteristics 
4.2.1 Catalytic properties 
Biochemical evidence has shown that HIV-1 protease catalyzes the proteolysis of gag and pol 
gene during formation of virion particle in the life-cycle of HIV (Luban et al., 1993; Debouck et 
al., 1987 and Katoh et al., 1985) and is highly specific to substrate recognition                   
(Luban et al., 1993). Herein, substrate binding and catalytic activity of I36TT variant protease 
was assessed in vitro using a chromogenic HIV-1 substrate which resembles HIV-1 protease 
cleavage site in the gag-pol polyprotein precursor. Comparing the substrate binding and catalytic 
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properties of the I36TT variant protease to that of the wild-type, it was discovered that the 
variant enzyme has a greater affinity for the substrate, with KM values of 193 µM and 89 µM for 
the wild-type and variant enzyme, respectively (Figures 16 and 17). See Table 3 for a summary 
of all the determined kinetic parameters. However, maximum velocities attained by the reactions 
catalyzed by these two enzymes were similar, with Vmax values of 0.0021 µmol.min-1 and   
0.0017 µmol.min-1 (Figures 16 and 17) for the wild-type and the variant enzyme, respectively.   
 
Catalytic activities of the wild-type and the variant protease enzyme were also assessed by 
determining the catalytic efficiency, kcat/KM, and turnover number, kcat. The latter is used to 
calculate how much of the substrate compound is converted to product per enzyme active site 
while the former measures how much substrate is converted to product per time. The I36TT 
variant enzyme proved to be more catalytically active as it converted more substrate compounds 
into product comparative to the wild-type. Turnover number and catalytic efficiency of the 
variant enzyme was increased almost two-fold as compared to that of the wild-type enzyme. This 
was demonstrated by kcat values of 0.10 s-1 and 0.18 s-1 (Figure 18) and kcat/KM values of       
0.007 µM-1.s-1 and 0.011 µM-1.s-1 (Figure 19) for the wild-type and the variant protease enzyme, 
respectively. Improved substrate binding, indicated by reduced KM, by the I36TT is implicated in 
the increased enzyme activity. However, these results are in contrast with those reported by 
Kozisek et al. (2008) which showed over five-fold decrease in the enzyme activity of an insert-
containing mutant protease (E35EE) relative to the wild-type HIV-1 subtype B.  
 
Taking into consideration the concentrations of the substrate and enzyme used in the reaction and 
the time taken by the reaction, specific activity of the enzymes was determined. Specific activity 
results showed a 7% difference in the catalysis of substrate hydrolysis by the I36TT variant 
protease relative to the wild-type. This was indicated by specific activity value of                     
2.9 µmol.min-1.mg-1 for the wild-type enzyme and 3.1 µmol.min-1.mg-1 for the variant. Catalytic 
characteristics determined in this study for the HIV-1 C-SA protease enzyme revealed that the 
I36TT mutation and background does not reduce the catalytic efficacy of the C-SA protease, but 
rather improves it slightly (7%).        
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4.2.2 Inhibition by ARVs 
Enzymatic characteristics of the wild-type and the I36TT variant protease were also assessed in 
the presence of four protease inhibitors employed in clinical settings during HIV-1 therapy. 
Nelfinavir, saquinavir, indinavir and ritonavir were individually included in the assays to assess 
the efficiency of the HIV-1 C-SA protease enzyme to catalyze hydrolysis of its substrate in the 
presence of inhibitors. IC50 values (amount of inhibitor needed to reduce the catalytic activity of 
the enzyme by 50%) for individual protease inhibitors were determined for the wild-type and the 
I36TT variant enzymes.  
 
Mutations at position 36 of the protease are associated with resistance to the protease inhibitor 
tipranavir in the subtype B HIV- 1 (de Mendoza et al., 2007). Insertions at this position lead to a 
decrease in susceptibility of the protease to the tipranavir and consequently improve viral fitness 
in the presence of this inhibitor. However, it is more likely that additional factors are also 
involved in the PR resistance to inhibitor caused by insertion mutations at this position. 
Comparison of insertion mutant structure to the subtype B wild-type has suggested that the 
insertion may influence the dynamics of flap movements during inhibitor binding and, thus, 
impaired flap movement may be implicated in weaker inhibitor binding in insert-containing 
mutants. However, this is not a general phenomenon for all protease inhibitors. Other insertion 
mutations detected in the protease region showed different response to various PIs. The 
M36TNL showed no resistance for all PIs tested and it was, therefore, proposed that this 
insertion does not contribute to resistance towards most of the FAD-approved protease inhibitors 
(Sturmer et al., 2003). 
 
Herein, like the wild-type, the variant enzyme did not show much resistance to the inhibitors. 
Catalytic activity of the C-SA proteases was significantly hindered by saquinavir with IC50 
values of 7.6 nM and 6.3 nM for the wild-type and the variant enzyme, respectively (Figure 20). 
However, the enzymes proved to be slightly more resistant to nelfinavir with IC50 values of   
17.3 nM for the wild-type enzyme and 16.8 nM for the variant (Figure 23). Additionally, the 
I36TT variant retained most of its enzymatic characteristics, with IC50 value of 36.4 nM, as 
compared to the wild-type protease (IC50 value of 19.1 nM) in the presence of ritonavir (Figure 
22). The same effects (IC50 value increased by 58%) were observed for the variant enzyme in the 
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presence of indinavir (with IC50 value of 16.2 nM) relative to the wild-type with IC50 value of     
9.5 nM   (Figure 21). See Table 4 for a summary of all the determined IC50 values.  
 
Comparing these results to others reported for other insert-containing protease mutants          
(Kim et al., 2001; Sturmer et al., 2003 and Kozisek et al., 2008), it may be proposed that amino 
acid insertion mutations confer PI resistance. Previous studies (Kozisek et al., 2008) assessed 
van der Waals distances between inhibitor (lopinavir) and residues within individual substrate 
binding subsites and they revealed a slight enlargement of the binding pockets due to 
rearrangement of neighbouring residues caused by insertions. This enlargement results 
specifically in the loss of van der Waals contacts between the amino acid side chain and the 
benzyl ring of lopinavir, and hence, weaker binding of the PI to the active site. Thus, this study 
reports that the I36TT insertion/mutation and its background polymorphisms do not show large 
differences in susceptibility to protease inhibitors but proffers protease considerable resistance 
towards ritonavir and indinavir. Further experimental work would be necessary to describe the 
role of background polymorphisms accompanying amino acid insertions in the protease coding 
region of HIV. 
 
4.3 Conclusion 
This study reports that the I36TT substitution/insertion and its background polymorphisms 
(P39S, D60E and Q61E), in the protease coding region of the South African HIV-1 subtype C, 
does not induce gross conformational alterations in the secondary and tertiary structure of the 
protein. The I36TT substitution/insertion mutant showed more than two-fold increase in affinity 
for the substrate and about two-fold increase in substrate turnover. The capability of the protease 
enzyme to cleave its substrate in the presence of various protease inhibitor drugs revealed that 
the I36TT variant protease is still catalytically active at ritonavir concentrations over 30 nM. 
These secondary mutations (mutations occurring outside the substrate binding cleft of the 
protease enzyme) have little effect on overall structure and inhibitor binding but they improved 
the proteolytic efficiency of the HIV-1 C-SA protease enzyme and hence improved viral 
maturation and replication rate. 
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